Foxa1 Upregulation Promotes Enhancer And Transcriptional Reprogramming In Endocrine-Resistant Breast Cancer
Xiaoyong Fu,Resel Pereira,Carmine De Angelis,Jamunarani Veeraraghavan,Sarmistha Nanda,Lanfang Qin,Maria L. Cataldo,Vidyalakshmi Sethunath,Sepideh Mehravaran,Carolina Gutierrez,Gary C. Chamness,Qin Feng,Bert W. O'Malley,Pier Selenica,Britta Weigelt,Jorge S. Reis-Filho,Ofir Cohen,Nikhil Wagle,Agostina Nardonek,Rinath Jeselsohn,Myles Brown,Mothaffar F. Rimawi,C. Kent Osborne,Rachel Schiff
DOI: https://doi.org/10.1073/pnas.1911584116
2019-01-01
Abstract:Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors. Hyperactive FOXA1 signaling due to gene amplification or overexpression has been reported in estrogen receptor-positive (ER+) endocrine-resistant metastatic breast cancer. However, the molecular mechanisms by which FOXA1 up-regulation promotes these processes and the key downstream targets of the FOXA1 oncogenic network remain elusive. Here, we demonstrate that FOXA1 overexpression in ER+ breast cancer cells drives genome-wide enhancer reprogramming to activate prometastatic transcriptional programs. Up-regulated FOXA1 employs superenhancers (SEs) to synchronize transcriptional reprogramming in endocrine-resistant breast cancer cells, reflecting an early embryonic development process. We identify the hypoxia-inducible transcription factor hypoxiainducible factor-2 alpha (HIF-2 alpha) as the top high FOXA1-induced SE target, mediating the impact of high FOXA1 in activating prometastatic gene sets and pathways associated with poor clinical outcome. Using clinical ER+/HER2(-) metastatic breast cancer datasets, we show that the aberrant FOXA1/HIF-2 alpha transcriptional axis is largely nonconcurrent with the ESR1 mutations, suggesting different mechanisms of endocrine resistance and treatment strategies. We further demonstrate the selective efficacy of an HIF-2 alpha antagonist, currently in clinical trials for advanced kidney cancer and recurrent glioblastoma, in reducing the clonogenicity, migration, and invasion of endocrine-resistant breast cancer cells expressing high FOXA1. Our study has uncovered high FOXA1-induced enhancer reprogramming and HIF-2 alpha-dependent transcriptional programs as vulnerable targets for treating endocrine-resistant and metastatic breast cancer.